Recent studies have shown that protein kinase C (PKC) δ is proteolytically activated at the onset of apoptosis induced by DNA-damaging agents, tumor necrosis factor, and anti-Fas antibody. However, the relationship of PKCδ cleavage to induction of apoptosis is unknown. The present studies demonstrate that full-length PKCδ is cleaved at DMQD330N to a catalytically active fragment by the cysteine protease CPP32. The results also demonstrate that overexpression of the catalytic kinase fragment in cells is associated with chromatin condensation, nuclear fragmentation, induction of sub-G1 phase DNA and lethality. By contrast, overexpression of full-length PKCδ or a kinase inactive PKCδ fragment had no detectable effect. The findings suggest that proteolytic activation of PKCδ by a CPP32-like protease contributes to phenotypic changes associated with apoptosis.
Skip Nav Destination
Article navigation
1 December 1996
Brief Definitive Report|
December 01 1996
Proteolytic Activation of Protein Kinase C δ by an ICE/CED 3-like Protease Induces Characteristics of Apoptosis
Tariq Ghayur,
Tariq Ghayur
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Margaret Hugunin,
Margaret Hugunin
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Robert V. Talanian,
Robert V. Talanian
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Sheldon Ratnofsky,
Sheldon Ratnofsky
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Christopher Quinlan,
Christopher Quinlan
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Yutaka Emoto,
Yutaka Emoto
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Pramod Pandey,
Pramod Pandey
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Rakesh Datta,
Rakesh Datta
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Yinyin Huang,
Yinyin Huang
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Surender Kharbanda,
Surender Kharbanda
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Hamish Allen,
Hamish Allen
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Robert Kamen,
Robert Kamen
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Winnie Wong,
Winnie Wong
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Donald Kufe
Donald Kufe
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Search for other works by this author on:
Tariq Ghayur
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Margaret Hugunin
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Robert V. Talanian
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Sheldon Ratnofsky
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Christopher Quinlan
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Yutaka Emoto
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Pramod Pandey
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Rakesh Datta
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Yinyin Huang
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Surender Kharbanda
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Hamish Allen
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Robert Kamen
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Winnie Wong
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Donald Kufe
From *BASF Bioresearch Corporation, Worcester, Massachusetts 01605; and ‡Division of Cancer Pharmacology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, Massachusetts 02115
Address correspondence to Donald W. Kufe, Division of Cancer Pharmacology, Dana-Farber Cancer Institute, 44 Binney St., Boston, MA 02115.
This investigation was supported by Public Health Service grants CA66996, CA55241, and CA29431 awarded by the National Cancer Institute, DHHS.
Received:
August 13 1996
Revision Received:
October 08 1996
Online ISSN: 1540-9538
Print ISSN: 0022-1007
1996
J Exp Med (1996) 184 (6): 2399–2404.
Article history
Received:
August 13 1996
Revision Received:
October 08 1996
Citation
Tariq Ghayur, Margaret Hugunin, Robert V. Talanian, Sheldon Ratnofsky, Christopher Quinlan, Yutaka Emoto, Pramod Pandey, Rakesh Datta, Yinyin Huang, Surender Kharbanda, Hamish Allen, Robert Kamen, Winnie Wong, Donald Kufe; Proteolytic Activation of Protein Kinase C δ by an ICE/CED 3-like Protease Induces Characteristics of Apoptosis. J Exp Med 1 December 1996; 184 (6): 2399–2404. doi: https://doi.org/10.1084/jem.184.6.2399
Download citation file:
Sign in
Don't already have an account? Register
Client Account
You could not be signed in. Please check your email address / username and password and try again.
Could not validate captcha. Please try again.
Sign in via your Institution
Sign in via your InstitutionEmail alerts
Advertisement